Intellia's CrispR gene therapy trial for HAE is not a risk to BCRX | BCRX Message Board Posts


BCRX   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  12746 of 12779  at  6/28/2021 2:31:47 PM  by

moshes


Re: Intellia's CrispR gene therapy trial for HAE is not a risk to BCRX

Yes, people should recognize that gene editing is not a precise science yet. It may be possible to edit some cells in vitro, then find and expand those that are just what you want, and use those in the patient. But as an efficient treatment, this is years away. Todays drop is a mistake. I expect a big jump as we approach the August 4 Q2 report.


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 1  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
12748 Re: Intellia's CrispR gene therapy trial for HAE is not a risk to BCRX kokopelli 0 6/28/2021 3:55:59 PM


Financial Market Data provided by
.
Loading...